This analysis confirmed both KGFR and FGFR2-IIIc down-modulation (0.3-fold and 0.2-fold, respectively, p < 0.01) in thyroid carcinomas (Fig. 7c). This evidence concerns the gene FGFR2 and thyroid gland carcinoma.